Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis.
BRCA
breast cancer
breast cancer prognosis
cancer susceptibility genes
neoadjuvant chemotherapy
surgery
young women
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Aug 2023
19 Aug 2023
Historique:
received:
31
07
2023
revised:
17
08
2023
accepted:
18
08
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Breast cancer (BC) is very uncommon in young women (YW) and it is unclear whether a BRCA mutation has prognostic implications. Our aim was to evaluate the characteristics of YW with BC by comparing the long-term oncological results between BRCA-mutation carriers and non-carriers. We retrospectively reviewed all the consecutive YW (aged 18-40 years) diagnosed with BC. Endpoints were disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS). 63 YW with a BRCA mutation were compared with 339 YW without BRCA mutation. BRCA-mutation carriers were younger (60.3% versus 34.8% if age ≤ 35 years, BC is more likely to present at a younger age (≤ 35 years) and with more aggressive characteristics (G3, triple-negative, Ki67 ≥ 25%) in YW with BRCA mutation compared with their non-mutated counterparts. Young BRCA-mutation carriers showed a poorer prognosis in terms of recurrence and survival compared with non-carriers. The implementation of neoadjuvant chemotherapy may improve survival in YW with BC and BRCA mutation.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer (BC) is very uncommon in young women (YW) and it is unclear whether a BRCA mutation has prognostic implications. Our aim was to evaluate the characteristics of YW with BC by comparing the long-term oncological results between BRCA-mutation carriers and non-carriers.
METHODS
METHODS
We retrospectively reviewed all the consecutive YW (aged 18-40 years) diagnosed with BC. Endpoints were disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS).
RESULTS
RESULTS
63 YW with a BRCA mutation were compared with 339 YW without BRCA mutation. BRCA-mutation carriers were younger (60.3% versus 34.8% if age ≤ 35 years,
CONCLUSIONS
CONCLUSIONS
BC is more likely to present at a younger age (≤ 35 years) and with more aggressive characteristics (G3, triple-negative, Ki67 ≥ 25%) in YW with BRCA mutation compared with their non-mutated counterparts. Young BRCA-mutation carriers showed a poorer prognosis in terms of recurrence and survival compared with non-carriers. The implementation of neoadjuvant chemotherapy may improve survival in YW with BC and BRCA mutation.
Identifiants
pubmed: 37627205
pii: cancers15164177
doi: 10.3390/cancers15164177
pmc: PMC10452863
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Breast Cancer Res. 2022 Dec 5;24(1):87
pubmed: 36471434
Clin Breast Cancer. 2021 Aug;21(4):329-336
pubmed: 33431329
J Clin Oncol. 2000 Dec 15;18(24):4053-9
pubmed: 11118466
Oncologist. 2013;18(12):1298-306
pubmed: 24277771
Ann Surg Oncol. 2006 Aug;13(8):1072-7
pubmed: 16865599
J Clin Oncol. 1994 May;12(5):888-94
pubmed: 8164038
Oncogene. 2006 Sep 25;25(43):5837-45
pubmed: 16998498
Lancet. 1998 Jan 31;351(9099):316-21
pubmed: 9652611
Int J Cancer. 2007 Sep 1;121(5):1017-20
pubmed: 17471561
Lancet Oncol. 2018 Feb;19(2):169-180
pubmed: 29337092
Breast Cancer Res. 2004;6(1):R8-R17
pubmed: 14680495
J Clin Oncol. 2008 Sep 10;26(26):4282-8
pubmed: 18779615
Curr Treat Options Oncol. 2019 Nov 27;20(12):86
pubmed: 31776799
Breast. 2022 Feb;61:77-83
pubmed: 34923225
Clin Cancer Res. 2022 Sep 1;28(17):3669-3676
pubmed: 35736816
BMC Cancer. 2009 Mar 19;9:86
pubmed: 19298662
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
Breast Cancer Res. 2014 Aug 27;16(4):427
pubmed: 25436920
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376189
Medicine (Baltimore). 2016 Oct;95(40):e4975
pubmed: 27749552
Lancet Oncol. 2017 Dec;18(12):1579-1589
pubmed: 29111259
Oncologist. 2012;17(6):775-82
pubmed: 22554997
N Engl J Med. 2007 Jul 12;357(2):115-23
pubmed: 17625123
Ann Oncol. 2012 Aug;23 Suppl 6:vi13-8
pubmed: 23012296
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Br J Cancer. 2016 Dec 6;115(12):1471-1478
pubmed: 27802449
J Clin Oncol. 2020 Feb 10;38(5):388-394
pubmed: 31461380
Cancer. 2000 Mar 15;88(6):1393-402
pubmed: 10717622
J Clin Oncol. 2012 Jan 1;30(1):19-26
pubmed: 22147742
BMC Cancer. 2018 Mar 22;18(1):315
pubmed: 29566657
J Clin Oncol. 2016 May 1;34(13):1460-8
pubmed: 26976419
Cancer Epidemiol. 2019 Oct;62:101573
pubmed: 31330422
J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45
pubmed: 9701363
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
PLoS One. 2015 Mar 27;10(3):e0120189
pubmed: 25816289
Eur J Surg Oncol. 2022 Aug;48(8):1706-1712
pubmed: 35534308
MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):43-47
pubmed: 35025856
J Clin Oncol. 2002 May 1;20(9):2310-8
pubmed: 11981002
PLoS One. 2019 Sep 6;14(9):e0222136
pubmed: 31491032
Front Oncol. 2020 Nov 09;10:592998
pubmed: 33304851
Cancer. 2018 Sep 1;124(17):3500-3509
pubmed: 30189117
J Clin Oncol. 2013 Sep 10;31(26):3191-6
pubmed: 23940229
Clin Cancer Res. 2012 Mar 1;18(5):1341-51
pubmed: 22261811
CA Cancer J Clin. 2020 Nov;70(6):443-459
pubmed: 32940362
JAMA Surg. 2017 Jun 1;152(6):589-594
pubmed: 28423155